The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 86 (high attention) · dilution pressure high · listing risk low · governance risk high · runway 6.1 mo · strongest signal: Auditor change (Jul 24, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway 6–12 months) coexists with live selling machinery (convertible note, shelf effective). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
The reported numbers themselves are in question — restatement, late filings or auditor churn. Treat the balance sheet with extra caution. A change of auditor or non-reliance on prior financials, together with late filings or a cluster of executive departures, is the pattern that precedes restatements, deregistration, or fraud allegations.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 13, 2026 | ▼ Convertible note | “convertible note” language in 8-K/A (EX-99.1) filed 2026-08-13 filing | 42 |
| Jul 29, 2026 | ▼ Shelf effective | EFFECT notice 2026-07-29 filing | 21 |
| Jul 29, 2026 | · Form 4 burst | 8 Form 4 filings in 30 days filing | 16 |
| Jul 24, 2026 | ▼ Auditor change | 8-K Item 4.01 filed 2026-07-24 (accepted 21:30 ET) filing | 67 |
| Jul 24, 2026 | · Change in control | 8-K Item 5.01 filed 2026-07-24 (accepted 21:30 ET) filing | 46 |
| Jul 24, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-24 (accepted 21:30 ET) filing | 40 |
| Jul 24, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-07-24 filing | 37 |
| Jul 24, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-07-24 (accepted 21:30 ET) filing | 33 |
| Jul 24, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-24 (accepted 21:30 ET) filing | 30 |
| Jul 22, 2026 | · 13D amendment | Schedule 13D/A filed 2026-07-22 filing | 24 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-6,296,833 as of 2026-06-30 filing | 31 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~6.1 months runway: liquidity $437,369 as of 2026-06-30, burn $867,204/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 27 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $437,369 vs current liabilities $3,628,077 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →